Trial Profile
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 18 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2020 Planned End Date changed from 31 Oct 2024 to 31 Oct 2027.
- 12 Nov 2020 Planned primary completion date changed from 31 Oct 2020 to 31 Oct 2023.